Eridosis

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Eridosis

What is Eridosis? Identity and Classification

Property Description
Active Ingredient Erythromycin (Single-ingredient product)
Form Pharmaceutical preparation (e.g., Tablets)
Pharmacological Class Macrolide Antibiotic
General Purpose Halting bacterial proliferation
Origin Polyketide origin (derived from natural sources)

Eridosis: Identity as a Macrolide Antibiotic

Eridosis is a branded medicinal product whose active ingredient is Erythromycin, which is classified as an effective antibacterial agent, commonly known as an antibiotic. Erythromycin belongs specifically to the macrolide pharmacological class, distinguished by its unique chemical structure, including a macrocyclic lactone ring. Eridosis is designated as a prescription-only medicine and is commonly supplied as an oral dosage form, such as tablets. This macrolide classification is clinically recognized for its efficacy against a range of susceptible bacteria, often presenting a therapeutic alternative when first-line antibiotics are unsuitable.


Composition, Origin, and General Purpose

The therapeutic function of Eridosis is derived solely from the single active compound, Erythromycin, which has a polyketide origin, indicating a chemical derivation from naturally occurring antimicrobial substances. As a pharmaceutical preparation, Eridosis tablets contain the exact dose of Erythromycin combined with specialized pharmaceutical excipients to optimize systemic route of administration.

The general purpose of Eridosis is to help resolve infectious diseases by targeting and controlling the growth of susceptible bacteria. By acting as a bacteriostatic agent, Erythromycin inhibits bacterial growth by stopping the production of essential proteins needed for bacterial growth. This mechanism ensures that the drug's core function is to halt microbial proliferation and aid the body's natural defense mechanisms.

What side effects are possible with Eridosis?

Possible Side Effects and Safety Information

The safety profile of Eridosis (Erythromycin) is defined by officially documented adverse reactions classified by both frequency and the specific body system affected. All information is based strictly on government regulatory documents.


Frequency and System-Organ Classes

The most frequently reported adverse reactions are generally classified as Common and involve the Gastrointestinal Disorders system. These typically include abdominal cramping, nausea, vomiting, abdominal pain, and diarrhea. Other system-organ classes involved include Hepatobiliary, Cardiac, Nervous System, and Skin disorders. Reactions classified as Rare include serious events such as cholestatic hepatitis and ventricular arrhythmias.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions. These include life-threatening Cardiac Arrhythmias, specifically QT prolongation which can lead to Torsade de Pointes, and significant liver injury such as Cholestatic Hepatitis. Furthermore, the medicine is officially associated with the risk of Infantile Hypertrophic Pyloric Stenosis (IHPS) when administered to young infants.

Safety constraints noted in the prescribing information include restrictions for use in patients with pre-existing conditions such as known QT interval prolongation or uncorrected hypokalemia or hypomagnesemia.


Population and Time-Related Safety

Safety considerations are explicitly noted for specific populations. Older adults may be at increased risk for drug-associated QT interval changes and hearing loss. For infants, the risk of IHPS is a primary concern. Additionally, a time-related pattern exists for Clostridium difficile-Associated Diarrhea (CDAD), which may be documented to occur even months after the antibacterial agent has been discontinued. The overall safety structure informs a clear, non-advisory view of the medicine's documented risks and limitations.

Overdose and Emergency Response

Overdose with Eridosis (Erythromycin) is primarily characterized by severe gastrointestinal manifestations, including marked nausea, vomiting, epigastric distress, and severe diarrhea. Of greater concern are the potential systemic effects. Regulatory documents indicate a documented risk of cardiotoxicity, specifically QT interval prolongation, which may lead to serious, life-threatening ventricular tachyarrhythmias, such as Torsades de Pointes. Transient hearing loss (ototoxicity) is also a reported clinical presentation associated with high exposure, particularly in patients with pre-existing renal or hepatic impairment.

Due to the potential for fatal cardiac events, the official regulatory guidance is that immediate medical attention must be sought for any suspected overdose. Emergency services or a Poison Control Center should be contacted without delay. There is no specific antidote known for Eridosis overdose. Management procedures described in official labeling focus on supportive care and the use of decontamination measures, such as gastric lavage and activated charcoal, to limit further absorption. Continuous ECG monitoring and close clinical observation are required elements of the management protocol to surveil for cardiotoxicity.

Therapeutic Uses of Eridosis

Eridosis is commonly used to provide symptomatic support for Acne Vulgaris, conditions presenting with systemic or localized discomfort. It is indicated for the topical treatment of this condition. The therapeutic benefits are applicable across domains where additional symptomatic support is needed, helping address symptoms that become more disruptive during flare-ups.

The medication is generally applied in clinical settings that involve conditions characterized by periods of heightened symptoms or episodes associated with acute or episodic changes. This assistance is commonly used to help with managing symptoms that interfere with daily functioning. It offers supportive relief that helps ease the overall symptom burden, and may assist with maintaining functional stability during symptomatic periods.

“The medication is considered relevant in contexts involving heightened systemic burden.”


Quick Fact: Therapeutic Support

Eridosis is generally used to help with managing acute and disruptive manifestations, supporting the patient during difficult episodes by easing distress and contributing to improved comfort during symptomatic periods.

Eligibility and Restrictions for Use

Absolute Contraindications

Eridosis is strictly contraindicated for several specific population groups. Use is prohibited for individuals with known hypersensitivity to Erythromycin or any macrolide antibiotic. It must also not be used by patients with a history of pre-existing cardiac conditions, including QT interval prolongation or ventricular cardiac arrhythmia. Furthermore, the medicine is contraindicated in the presence of uncorrected electrolyte imbalances like hypokalemia or hypomagnesemia.

Restricted and Conditional Use

Official labeling requires caution and monitoring for patients with impaired hepatic function due to the drug's primary excretion route. Caution is also necessary for individuals with conditions such as Myasthenia Gravis, as symptoms may be exacerbated.

Use is restricted in infants, particularly those under 14 days old, due to the documented risk of Infantile Hypertrophic Pyloric Stenosis (IHPS). For pregnancy, use is considered conditionally acceptable but reserved for situations where it is clearly needed. The medicine is generally compatible with lactation, though monitoring is advised.

What should I know about interactions with other medicines?

Eridosis Interactions with other medicines and products

Eridosis, a macrolide antibiotic related to Erythromycin, has a recognized potential for significant drug-drug interactions due to its role as an inhibitor of the Cytochrome P450 (CYP) 3A enzyme system in the liver. This inhibition can lead to decreased metabolism and thus elevated blood levels of many other medicines, increasing the risk of adverse effects from the co-administered drug.

Key interacting drug categories include:

Interacting Category Interaction Mechanism / Outcome Significance
Statins (e.g., simvastatin, lovastatin) Elevated statin levels, increasing risk of muscle toxicity (rhabdomyolysis). Clinically Significant
Oral Anticoagulants (e.g., warfarin) Increased anticoagulant effect, raising the risk of bleeding. This effect may be more pronounced in older adults. Use with Caution
Ergot Alkaloids (e.g., ergotamine) Markedly increased levels of ergotamine, leading to potential ergot toxicity (vasospasm/loss of blood flow). Contraindicated
Certain Cardiac Drugs (e.g., digoxin, verapamil) Elevated concentrations of the cardiac drug, increasing the risk of toxicity (e.g., elevated digoxin levels or hypotension with verapamil). Use with Caution

Co-administration with other medicines that prolong the QT interval on the electrocardiogram should be avoided, as this combination may increase the risk of serious cardiac arrhythmias like Torsades de pointes. This includes antiarrhythmics. If theophylline is co-administered, its serum levels must be closely monitored, as Eridosis may either increase or decrease theophylline concentrations.

Mechanism of Action

Inhibiting Bacterial Protein Synthesis

Eridosis, through its active ingredient Erythromycin, operates via a primary molecular mechanism that interferes with the essential protein synthesis pathway of susceptible bacteria. Erythromycin specifically binds to the 23S ribosomal RNA (rRNA) within the 50S ribosomal subunit of the bacterial 70S ribosome. This binding event physically obstructs the nascent peptide exit tunnel, which is the channel through which polypeptide chains must exit the ribosome. This molecular interference prevents the necessary translocation step and assembly of new protein chains, resulting in the cessation of bacterial replication and growth.

Modulating Host Gastrointestinal Motility

Separately from its antimicrobial function, Eridosis acts upon mechanisms that influence the host's digestive system. The drug acts as an agonist by binding to and activating the Motilin Receptors found on the smooth muscle cells of the gastrointestinal tract. This action initiates strong, synchronized muscle contractions, resulting in altered gastrointestinal motility and modification of contents transit.

Dosage and Administration Information

How to Use Eridosis: Official Administration Guidelines

Eridosis (Erythromycin) is administered via several approved routes, including Oral (tablets, capsules, suspension), Intravenous (IV), and Topical application, depending on the clinical scenario. Standard instructions define precise administration parameters across all available dosage forms, which include immediate-release tablets, delayed-release capsules, and oral suspensions.


Standard Systemic Dosing and Frequency

For adult systemic use, the typical regimen for Erythromycin is 250 mg every 6 hours (Q6H), 333 mg every 8 hours (Q8H), or 500 mg every 12 hours (Q12H), with dosing divided into 2 to 4 intervals per day. The maximum recommended daily dose for severe infections is 4,000 mg (4 g). Pediatric dosing is determined by weight, commonly calculated between 30 to 50 mg/kg/day. For certain acute infections, the systemic treatment course is maintained for a minimum of 10 days.


Administration Conditions and Constraints

The method of intake is often dictated by the formulation. Immediate-release oral forms are best absorbed when administered in a fasting state, generally 30 minutes to 2 hours before a meal. A critical handling instruction is that delayed-release tablets or capsules must not be crushed or chewed. For topical administration, the medicine is applied twice a day to the affected area only after the skin has been thoroughly washed and dried. For topical use, treatment is typically re-evaluated if no improvement is observed after 6 to 8 weeks.


Classification Administration Detail
Route of Administration Oral, Intravenous (IV), Topical
Frequency Pattern Fixed interval (Q6H, Q8H, Q12H) for systemic use
Topical Frequency Twice Daily to cleansed, dry skin

Recent Clinical Evidence

Research evidence / Overview of Studies for Eridosis

The evidence summarized here describes the formal research used by regulators to evaluate Eridosis and the specific conditions that research examined. The information reflects findings observed in study settings and highlights what remains uncertain.


Evidence for Use in Acne Vulgaris (Topical)

The basis for the regulatory decision regarding Eridosis applied topically for Acne Vulgaris rests on clinical trial evidence that has been reviewed by government health authorities, such as the U.S. Food and Drug Administration (FDA). The regulatory labeling for this use is based upon research that examined the application of the medicine directly to the affected area.

Research explored how symptoms change over time when the medicine was evaluated in studies focusing on episodes where symptoms become more noticeable. These studies monitored research outcomes focused on inflammatory or irritative states and included patient-reported outcomes describing perceived discomfort.

Studies reported measurements of patterns observed in the studies related to outcomes linked to inflammatory or irritative states. The evidence contributes to the broader evidence landscape by helping contextualize how patients reported their experience during these short-term studies.


Long-Term Studies and Follow-Up

The provided regulatory summaries for Eridosis do not specify the typical follow-up durations of the pivotal clinical trials. Therefore, the extent of data available for long-term outcomes and the durability of any observed changes are not fully established in the high-level evidence summary.

Research provides context regarding short-term changes under the specific conditions of the clinical trials, but information regarding how symptoms evolved over extended time intervals beyond the study periods is often limited. Therefore, long-term effects are not fully established based on the summarized evidence.


Evidence in Specific Patient Groups

The high-level summaries of the evidence base do not specify the particular demographics of the populations studied in the primary clinical trials, such as specific age groups or varying severity strata. This means data for certain groups, including very young or older adults, remain insufficient in the public summaries.

Details regarding research outcomes for patients with comorbid conditions—conditions where symptoms may vary in intensity or those presenting with cycles of stability and flare-ups—are not specified in the public summaries. Consequently, the applicability of the findings to these subgroups is uncertain. The results apply only to the populations studied in the research and do not predict individual responses.


Reviewing the Strength and Gaps in Evidence

The explicit indication for the use of Eridosis in Acne Vulgaris within official regulatory documentation is based on clinical evidence that met the necessary threshold for regulatory authorization.

However, detailed findings are limited because many research limitation frames were not specified in the public summaries. For instance, subgroup findings are uncertain, and information regarding the comparative evidence is lacking in the high-level regulatory summary.

The evidence highlights what is known—and what is still uncertain. The findings describe group patterns, not personal outcomes, and the research provides context but not individual predictions. Research gaps remain in understanding symptom patterns in conditions characterized by fluctuating or episodic manifestations.

Frequently Asked Questions (FAQ)

Common questions about Eridosis (FAQ)

Q: What is the main reason Eridosis is prescribed?

A: According to official product information, Eridosis is approved for treating a range of bacterial infections, including those affecting the respiratory tract, skin, and certain sexually transmitted infections. The medicine's regulatory indications also cover conditions such as intestinal amebiasis. Additionally, Eridosis is indicated as a topical treatment for acne vulgaris after being reviewed by government health authorities.


Q: How quickly can someone expect to notice the effects of Eridosis?

A: The time it takes to notice the effects of Eridosis can depend on the condition being treated. For acute infections, clinical observations suggest that symptoms may begin to improve within a few days. However, when Eridosis is used as a topical treatment for skin conditions like acne, regulatory-supported studies indicate that it may take several weeks or even months to observe improvement.


Q: How long does Eridosis typically stay in your system?

A: Official pharmacokinetic data describes how Eridosis is processed by the body, noting that it has a relatively short elimination half-life. This means the body processes and removes the drug quite quickly. The medicine is primarily cleared from the body by the liver and excreted into the bile, with only small amounts recovered in the urine.


Q: Is Eridosis considered a controlled substance?

A: The official classification of Eridosis by government regulatory agencies indicates that it is not considered a controlled substance. While it is a non-controlled medicine, it is still designated as a prescription-only product.


Q: Are there any common supplements that should be avoided while taking Eridosis?

A: Official regulatory guidance advises general caution regarding the use of supplements or herbal remedies while taking Eridosis. This is because these products are generally not subjected to the same standardized testing for drug interactions as prescription medicines. This is relevant because the interaction profile may not be fully established in the same regulatory manner.


Q: Is it common to feel tired or dizzy when starting Eridosis?

A: While not frequently reported, official prescribing information does mention certain adverse reactions that may affect the nervous system. These include reports of dizziness, unusual tiredness or weakness, and somnolence (drowsiness) among the less frequent side effects. This information helps contextualize potential less-common experiences when starting the medication.


Q: Does Eridosis cause weight gain or weight loss?

A: Regulatory adverse event reports have documented mentions of loss of appetite and resulting unusual weight loss. However, weight gain is not specifically listed among the frequently reported or otherwise documented side effects in the official prescribing information.


Q: Are there different brand names for the same medicine as Eridosis?

A: Yes, the active ingredient in Eridosis, which is Erythromycin, is available worldwide under various different brand names. Examples include Erythrocin, Eryped, Erymax, and Erythroped.


Q: Can Eridosis be taken by people with kidney problems?

A: Official prescribing information indicates that Eridosis is primarily processed and excreted by the liver. Regulatory prescribing information states that caution and monitoring are required for use in patients with impaired renal function (kidney function), and older patients may face an increased risk of kidney-related issues.


Q: What is the risk of dependence or addiction with Eridosis?

A: Eridosis is classified by regulatory agencies as a non-controlled antibiotic medication. Its official prescribing information does not note any established risk of dependence or addiction associated with its use.


Q: Does Eridosis interact with common pain relievers like ibuprofen or acetaminophen?

A: Regulatory-based interaction databases generally do not find a major interaction between Eridosis (Erythromycin) and common over-the-counter pain relievers such as ibuprofen or acetaminophen. Official guidance notes that general caution is relevant because the drug has a broad potential for affecting the metabolism of other medications.


Q: Can alcohol be consumed while taking Eridosis?

A: Regulatory-based guidance suggests that there is generally a minor interaction between Eridosis and alcohol. Some authoritative sources note that alcohol consumption may potentially reduce the medicine's effectiveness or delay how quickly it starts to work.


Q: What happens if a dose of Eridosis is missed?

A: The official guideline for a missed dose is included in the patient information section of the drug label. This guidance specifies the steps to take, including when a dose should be skipped to prevent doubling the amount taken. This official information helps guide patients on maintaining their prescribed regimen.


Q: Can Eridosis affect blood pressure?

A: The official product label does not explicitly list changes in blood pressure as a frequent adverse reaction. However, Eridosis is associated with serious Cardiac Arrhythmias (abnormal heart rhythms), specifically QT prolongation. These cardiac effects are noted in the safety information and may be linked to overall cardiovascular function.


Q: Does Eridosis make birth control less effective?

A: Regulatory evidence regarding the interaction between Eridosis and hormonal birth control is considered mixed. Some data indicates that the medicine may increase the blood levels of certain estrogen components. Conversely, other evidence suggests that, as an antibiotic, Eridosis may reduce the effectiveness of hormonal birth control methods.


Q: Why is Eridosis sometimes prescribed along with another medication?

A: Eridosis is sometimes prescribed as part of a combination treatment regimen. This is commonly seen when treating conditions such as acne vulgaris, where it may be used alongside other agents like benzoyl peroxide. It is also combined with other medicines to treat certain serious infections, such as diphtheria, to maximize therapeutic results.


Q: Can Eridosis cause headaches?

A: Official prescribing information reports headaches as a documented adverse reaction to the medication. This effect is typically classified under the list of side effects that relate to the Nervous System.


Q: Does Eridosis affect sleep patterns?

A: Eridosis is associated with certain effects on the Nervous System. These effects, which are documented in regulatory sources, include somnolence (drowsiness) and, less frequently, temporary central nervous system side effects that could potentially impact sleep patterns.


Q: Does Eridosis have an impact on mood or energy levels?

A: Regulatory documents report certain general side effects that might impact overall well-being, including malaise (a general feeling of discomfort), confusion, and irritability (especially noted in infants). While changes in mood and energy are not specifically defined, these effects suggest a potential impact on the patient's general disposition.


Q: Does the efficacy of Eridosis change over time?

A: Official documents confirm that bacterial resistance can develop against Erythromycin. This occurs when bacteria adapt their internal structure, preventing the drug from working as intended. This resistance is a known factor that can lead to a reduction in the medicine's efficacy over time.


Q: Are there known risks if Eridosis is taken by someone who doesn't need it?

A: Official regulatory warnings state that the medicine is reserved for treating or preventing infections documented or strongly suspected to be caused by susceptible bacteria. Using the medicine unnecessarily exposes the individual to the full spectrum of documented adverse effects and contributes to the public health issue of drug-resistant bacteria.


Q: What kind of specialist typically prescribes Eridosis?

A: Because Eridosis treats a wide variety of conditions, it is commonly prescribed by various medical professionals. These specialists include General Practitioners (GPs) for common infections, Dermatologists for skin conditions like acne, and Infectious Disease Specialists for more complex cases.


Q: Is there a generic version of Eridosis available?

A: Yes, the active ingredient in Eridosis, Erythromycin, has been reviewed by regulatory bodies and has approved generic versions available. These generic products may be marketed under the name Erythromycin or under other separate brand names.


Q: Are there any documented interactions between Eridosis and herbal teas?

A: Specific interactions involving individual herbal teas are not generally documented in the official regulatory information for Eridosis. The official guidance advises general caution because the interaction profile may not be fully established.


Q: Is the research for Eridosis still ongoing, or are studies complete?

A: While Eridosis received regulatory approval based on its primary clinical trials, scientific research into macrolide antibiotics is continually ongoing. This includes studies examining long-term effects, evolving resistance patterns, and potential new uses for the medication.

How should Eridosis be stored and disposed of?

How to Store and Dispose of Eridosis?

Regulatory documents mandate specific storage conditions for Eridosis (Erythromycin tablets) to ensure product stability and safety.


Storage Requirements

Detail Condition
Temperature Store at controlled room temperature (20 C to 25 C); avoid excessive heat.
Protection Keep the product in a tightly closed container and protect it from moisture.
Child Safety Eridosis must be stored out of the reach of children.

Disposal Instructions

Official guidelines state that unused or expired Eridosis must not be flushed down the toilet. Dispose of the medication using a drug take-back program or follow the specific safe disposal instructions provided by the FDA or local authorities.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Eridosis found in:

A-Z Index: